Welcome to our dedicated page for Petvivo Holdings SEC filings (Ticker: PETVW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PetVivo Holdings, Inc. (PETVW) filings document material events for a veterinary biomedical device company operating through PetVivo Animal Health and PetVivo AI. Recent Form 8-K disclosures cover material definitive agreements, unregistered sales of equity securities, subscription-agreement financing, and capital-structure changes involving restricted common stock.
The company’s filings also record governance changes, including director resignations and board-size reductions, along with Regulation FD investor-presentation materials. These disclosures frame PetVivo’s public-company reporting around financing activity, board composition, subsidiary operations, veterinary medical products and investor communications.
PetVivo Holdings, Inc. reporting person John Lai, who serves as Chief Executive Officer and a director, reported a non‑derivative acquisition on 09/18/2025. The filing shows a grant of 84,375 shares of common stock at a price of $0.76 to a corporation owned by the reporting person as compensation for past performance, reflecting conversion of a past accrued bonus into common stock. Following the transaction, the reporting person (indirectly) beneficially owned 2,020,710 shares. The Form 4 is signed by John Lai on 09/22/2025. The filing indicates the award was issued as compensation rather than a market purchase.
Garry Lowenthal, Chief Financial Officer of PetVivo Holdings, Inc., received a grant of restricted common stock on 09/18/2025 as compensation for past performance. The grant consisted of 79,375 shares at a stated price of $0.76 and was issued to a corporation owned by Mr. Lowenthal. After the reported transaction, the reporting persons indirect beneficial ownership totaled 592,967 shares. The Form 4 indicates this was a non-derivative award recorded as an acquisition and identifies the grant as compensation rather than a market purchase.